FivepHusion has a multi-disciplinary research team under the stewardship of Professor Phil Clingan and A/Prof. David Ziegler, prominent Australian oncologists, together with a distinguished medicinal chemist, Emeritus Professor John Bremner and Professor Marie Ranson, a notable cell biologist from the University of Wollongong. Its clinical trials have been undertaken at the Southern Medical Day Care Centre in Wollongong and at the Liverpool Hospital in Sydney, Australia.
| Christian Toouli is CEO and Managing Director of FivepHusion. Christian is a motivated and resourceful biotechnology executive, dedicated to the development and commercialisation of breakthrough medicines for patients and to creating value for shareholders. Over the last fifteen years Christian has served as the Executive Director of Bio-Link Australia, a global business development and strategic advisory company headquartered in Sydney, working on behalf of the company’s Australian and international biotechnology clients to achieve commercial outcomes for their assets. During this time, he facilitated numerous commercial agreements, including license and collaboration agreements on behalf of a broad range of clients for their therapeutic, diagnostic and research assets. He also co-founded two biotechnology companies developing cutting edge therapeutic platform technologies.|
Previously, Christian was a Postdoctoral Fellow in the Discovery Research Department of Schering-Plough Biopharma/DNAX Research Institute, the biotechnology arm of Schering-Plough Corporation. Christian received his PhD from the University of Sydney for his research into cellular immortalisation and telomere maintenance at the Children’s Medical Research Institute. He was awarded a Certificate in Biotechnology Management with Honours from the University of California, Santa Cruz Extension, and First-Class Honours in Biotechnology from Flinders University of South Australia. Christian is also a graduate of the Australian Institute of Company Directors.
|David Ranson is Executive Chairman of FivepHusion. David is an entrepreneur at heart, and has been a director of several research and development focused companies over the past 33 years. |
As Chairman of FivepHusion, David has overseen the development of Deflexifol for 7 years, managing two clinical trials and conducting pharmaceutical business development including presentations at JP Morgan, BIO and throughout Asia. He has managed in-licensing and out-licensing efforts, regulatory engagement and drug manufacture, and has conducted three successful capital raisings to fund the company's development.
Since graduating in 1986 in Electrical Engineering with First Class Honours from the University of NSW, David has worked in product development in both Australia and the USA.
|Bill Ketelbey Dr Ketelbey is an Executive Director of FivepHusion. Bill is a highly experienced and successful executive in the healthcare and pharmaceutical sector, with more than 30 years’ experience leading the development of numerous drugs across a broad range of therapeutic areas. Most recently, Dr Ketelbey championed the development of a breakthrough Alzheimer’s drug as CEO and Managing Director of Actinogen Medical, an ASX listed biotech company. Prior to that, he held senior medical and management roles within the global pharmaceutical giant, Pfizer, including Regional Vice President APAC, Senior Vice-President/Senior Medical Director Japan and Country Medical Director ANZ|
Dr Ketelbey has a medical degree from the University of the Witwatersrand (South Africa), is a Fellow of the Faculty of Pharmaceutical Medicine with the Royal College of Physicians (UK), has an MBA from Macquarie University (Australia), and is a Graduate of the Australia Institute of Company Directors.
Dr Ketelbey is a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and chairs the IP and Commercialisation Committee at WIMR
|Phil Clingan graduated from the University of NSW in 1978 and is a Fellow of the Royal Australian College of Physicians. Phil has participated in over 100 international clinical trials, including the FOLFOX trial.|
|David Ziegler is a Senior Staff Specialist in the Kids Cancer Centre at Sydney Children’s Hospital and has expertise in neuro-oncology and early phase clinical trials. He completed his clinical training in paediatric haematology and oncology at Sydney Children’s Hospital. From 2005-2007 he was a Fulbright Scholar at the Dana Farber Cancer Institute, Harvard Medical School and Children’s Hospital Boston. He is a Conjoint Associate Professor at the University of New South Wales and a Group Leader at the Children’s Cancer Institute (CCI), where his preclinical research focuses on novel therapies for childhood brain tumours. He is deputy director of the Kids Cancer Alliance – a translational research program supported by the Cancer Institute NSW.|
| Marie Ranson is a Teaching and Research Academic at University of Wollongong. Marie is also the Illawarra Lead and Deputy Director of the Cancer Institute NSW funded CONCERT Translational Cancer Research Centre. She has held appointments as the Cancer Scientific Director at the Illawarra Health and Medical Research Institute, acting Head of School of Biological Sciences and held a Cancer Institute Career Development Fellowship. Prior to this, she held a Fogarty post-doctoral fellowship at the National Institutes of Health, Bethesda MD, USA. Read more.|
|John Bremner was Professor of Organic Chemistry in the Department of Chemistry, University of Wollongong from 1991-2007, and is currently an Emeritus Professor of the University. His research interests cover medicinal chemistry (particularly new anti-bacterial and anti-cancer agents), heterocyclic chemistry, and natural products. In 2001 he received the Adrien Albert Award of the RACI’s Division of Biomolecular Chemistry for his contributions to medicinal chemistry, and received the Halpern Medal (School of Chemistry, Wollongong) in 2008. He is a Fellow of The Royal Australian Chemical Institute (Distinguished Fellowship Award 2011) and a Fellow of The Royal Society of Chemistry.|